Skip to main content
David Asmuth, MD, Infectious Disease, Sacramento, CA, Sacramento Veterans Affairs Medical Center

DavidMichaelAsmuthMD

Infectious Disease Sacramento, CA

HIV/AIDS Medicine

Associate Professor, Division of Infectious Diseases, Dept. of Internal Medicine, UC Davis Med. Ctr

Dr. Asmuth is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Asmuth's full profile

Already have an account?

Education & Training

  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterPost-Doctoral Fellowship, Medicine-Preliminary, 1990 - 1993
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterFellowship, Infectious Disease, 1988 - 1990
  • U Washington Affil Hosps
    U Washington Affil Hosps1988 - 1989
  • University of Washington
    University of WashingtonResidency, Internal Medicine, 1986 - 1988
  • University of Wisconsin Hospitals and Clinics
    University of Wisconsin Hospitals and ClinicsInternship, Internal Medicine, 1985 - 1986
  • Northwestern University The Feinberg School of Medicine
    Northwestern University The Feinberg School of MedicineClass of 1985

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 1986 - 2026
  • CA State Medical License
    CA State Medical License 2002 - 2026
  • TX State Medical License
    TX State Medical License 1994 - 2002
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Nominated for Excellence in Teaching Award Department of Internal Medicine, 1999
  • Humanism in Medical Education Award AAMC UTMB nominee, 1999

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Physiological effects of human immunodeficiency virus (HIV) infection on human intestinal epithelial cells: an in vivo model for HIV enteropathy.  
    Asmuth DM, Hammer SM, Wanke CA, AIDS
  • Clinical features of Microsporidiosis in patients with AIDS.  
    Asmuth DM, DeGirolami PC, Federman M, Ezratty CR, Pleskow DK, Desai G, Wanke CA, Clin Infect Dis
  • Diagnosis of intestinal Microsporidiosis by microscopic examination of stool and duodenal aspirate with Weber's modified trichrome and uvitex 2B stains  
    DeGirolami PC, Ezratty CR, Desai G, McCullough A, Asmuth DM, Wanke CA, Federman M, J Clin Micro
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • HIV infection of HT-29 intestinal cells: A model of HIV enteropathy.
    Asmuth DM, Hammer SM, Wanke CA, Abstracts of the American Society for Microbiology, New Orleans, LA
  • Clinical features of Microsporidiosis in patients with Acquired Immunodeficiency Syndrome.
    Asmuth DM, DeGirolami PC, Federman M, Ezratty CR, Pleskow DK, Desai G, Wanke CA, Abstracts of the Infectious Diseases Society of America, New Orleans, LA
  • Effects of Clostridium perfringens recombinant and crude phospholipase C and ? toxins on rabbit hemodynamic parameters.
    Asmuth DM, Asmuth DM, Olsen RD, Bryant AE, Tweten RK, Tso JY, Hackett SP, Zollman T, Stevens DL, Abstracts of the Conference on the Molecular Genetics and Pathogenesis of the Clostridia, Tuscon, AZ
  • Join now to see all

Press Mentions

  • Clinical Trial Launched to Analyze Bovine-Derived Immunoglobulins for Preventing COVID-19 Side Effects
    Clinical Trial Launched to Analyze Bovine-Derived Immunoglobulins for Preventing COVID-19 Side EffectsFebruary 18th, 2021
  • SARS-CoV-2 Induces Robust Germinal Center CD4 T Follicular Helper Cell Responses in Rhesus Macaques
    SARS-CoV-2 Induces Robust Germinal Center CD4 T Follicular Helper Cell Responses in Rhesus MacaquesJanuary 22nd, 2021
  • Sofosbuvir and Ribavirin for Hepatitis C in Patients with HIV Coinfection
    Sofosbuvir and Ribavirin for Hepatitis C in Patients with HIV CoinfectionSeptember 19th, 2019
  • Join now to see all

Grant Support

  • Cell Cycle Regulation In Peripheral Blood And Lymph Node Lymphocytes From HIV InNational Center For Research Resources2004
  • Multicolor Flow Users Network StudyNational Institute Of Allergy And Infectious Diseases2002–2004
  • Viral Load In Cellular Subcompartments Following HaartNational Institute Of Allergy And Infectious Diseases2001–2003
  • Quantitative In Situ Hybridization--Hiv1 RNA Clearance From Lymphoid TissueNational Center For Research Resources1998–2002
  • Viral Load In Cellular Subcompartments Following HaartNational Institute Of Allergy And Infectious Diseases1999–2001

Committees

  • Journal Reviewer, Clinical Infectious Diseases 2012 - Present
  • Journal Reviewer, Journal of Infectious Diseases 2012 - Present
  • Journal Reviewer, AIDS 2012 - Present
  • Journal Reviewer, Journal of Immunology 2012 - Present
  • Journal Reviewer, Cytometry 2012 - Present
  • Journal Reviewer, Antiviral Research 2012 - Present
  • Journal Reviewer, British Journal of Pharmacology 2012 - Present
  • Member, Industry Vendor Relations Committee - UCDMC 2008 - Present
  • Chair, IRB Committee A 2004 - Present
  • Associate Director, CTCS Clinical Research Center (formerly the General Clinical Research Center) - UCDMC 2004 - Present
  • Member, Clinical Research Compliance Oversight Committee – UCDMC 2003 - Present
  • Member, CTSC Resources Review Committee (formerly: General Clinical Research Center Advisory Committee) - UCDMC 2003 - Present
  • Member, College of Science Advisory Council - University of Notre Dame 2001 - Present
  • UTMB ’95 – ’02; UCDMC ’02- present, Institutional Review Board member 1995 - Present
  • Member, Immunology Research Agenda Committee; ACTG 2001 - 2004

Research History

  • An International, Prospective Observational Study of the Safety of Maraviroc Used with Optimized Background Therapy in Treatment Experienced HIV-1 Infected Patients Pfizer 10672012 - Present
  • A Phase 2B/3 Open-Label Rollover Study for Subjects Discontinuing From the UK-453,061 Protocols for the Treatment of HIV-1 Infected Subjects Pfizer 10382012 - Present
  • A Phase 2B, Multicenter, Randomized, Comparative Trial of UK-453,061 Versus Etravirine in Combination with Darunavir/Ritonavir and an Nucleotide/Nucleoside Reverse Transcriptase Inhibitor for the Treatment of Antiretroviral Experienced HIV-1 Infected Subj2012 - Present
  • CCRC: FITNESS: A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Filibuvir Plus Pegylated Interferon Alfa 2a and Ribavirin in Treatment Naïve, HCV Genotype 1 Infected Subjects Pfizer 10142012 - Present
  • CCRC: A Phase II, Randomized, double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination with Pegylated Interferon and Ribavirin in Subjects with Genotype 1 Chronic Hepatitis C Idenix2012 - Present
  • A Study of HIV-Infected Subjects Initiating AT for the First Time for the Purpose of Obtaining Pre-Therapy HIV RNA to Qualify Subjects for the Subsequent HIV RNA-Electroplated Dendritic Cell Immunization Study Argos Therapeutics2012 - Present
  • CCRC: Pharmacologic characteristics of Efavirenz, Emtricitabe, and Tenofovir Disoproxil Fumarate fixed dose combination in rectal mucosa as compared to peripheral blood. Gilead Inc. Investigator Initiated2012 - Present
  • CCRC: A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy. Pfizer, Inc. Investigator Initiated2012 - Present
  • CCRC: A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Raltegravir Therapy Merck & Co., Inc.2012 - Present
  • A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x versus Placebo in Patients Infected with HIV-1 Who Have Maintained an Adequate Response to ART2012 - Present
  • “A Phase I Dose Ranging Study of the Safety, Tolerability, and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 Trigene and the MRKAd6 HIV-1 Trigene Vaccines Alone and in Combination in Healthy Adults” Merck & Co., Inc., PROTOCOL No V520-0012012 - Present
  • A Phase I Dose-Ranging Study of the Safety, Tolerability, and Immunogenicity of the Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef Vaccine (MRKAd5 HIV-1 gag/pol/nef) in a Prime-Boost Regimen in Healthy Adults. Merck & Co., Inc PROTOCOL No.: 016-2012 - Present
  • A Study of the Safety, Tolerability, and Immunogenicity of Human Immunodeficiency Virus Type 1 (HIV-1) gag DNA Vaccine Formulated with CRL1005 Adjuvant, or with Aluminum Phosphate (AlPO4), Followed by Ad5 HIV-1 gag Vaccine (Adenovirus Serotype 5 HIV-1 gag2012 - Present
  • Clinical Translational Science Award NIH, UL1 RR024146 Berglund (PI2006 - Present
  • Immunology Support Laboratory at UC Davis Social and Scientific Systems, Inc.2001 - 2012
  • Biology of HIV in Minorities University of California Wide AIDS Research Program (UARP) Pollard (PI)2005 - 2010

Hospital Affiliations